{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-042478","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.719092+00:00","generated_at":"2026-05-30T17:55:13.078836+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo doses first patient in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa","bullets":["Phase 2 LOTUS trial enrolling ~180 adults with moderate to severe hidradenitis suppurativa.","Two dose regimens of AVTX-009 vs placebo in 1:1:1 randomization over 16-week treatment phase.","Primary endpoint: proportion achieving HiSCR75 at Week 16; topline data expected in 2026.","CEO Garry Neil cited high potency potential for best-in-class treatment option.","AVTX-009 is a humanized monoclonal antibody targeting IL-1β with high affinity."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-042478","json":"https://secwatch.observer/filing/0001628280-24-042478.json","markdown":"https://secwatch.observer/filing/0001628280-24-042478.md","text":"https://secwatch.observer/filing/0001628280-24-042478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024042478/0001628280-24-042478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024042478/avtx-20241008.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:55:13.078836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}